Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 2,000
- 试验地点
- 6
- 主要终点
- SAFETY and TOLERABILITY Outcomes
研究概览
简要总结
Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.
Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.
Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).
Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups.
Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.
LABORATORY TESTING:
Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.
Where in Urine Routine Examination (Urine R/E), we consider as follows:
-
Visual Examination:
-
Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.
-
Urine clarity: Clear, slightly Cloudy, cloudy or turbidity
-
Chemical Examination:
-
Specific gravity
-
pH
-
Bilirubin
-
Urobilinogen
-
Protein
-
Ketone
-
Leukocyte Esterase
-
Microscopic Examination:
-
Red Blood Cells:
-
Epithelial Cells:
-
Amorphous:
-
Pus Cells
-
Bacteria
-
Yeast
-
Casts
-
Crystals
Where in Renal Function Test (RFT), we consider as follows:
- Blood Urea Nitrogen (BUN): mg/dL
- Serum Creatinine: mg/dL
- Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.
排除标准
- •Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.
研究组 & 干预措施
Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months
Type 2 diabetic males & females between 18-65 years.
- HbA1c: 7.0% - 10%
- eGFR ˃60 mL/min/1.73m2.
- Patient who will give informed consent
干预措施: Empagliflozin (Drug)
结局指标
主要结局
SAFETY and TOLERABILITY Outcomes
时间窗: 6 months
Frequency of adverse events, serious adverse events during the course of study follow-up. Percentage of patients who tolerate empagliflozin.
次要结局
- Efficacy outcomes(6 months)
